Let's not forget their analytics division is doing OK and will continue to grow, irregardless of what happens with their Promarker tech.
$1.129M collected last fy on analytics alone.
Fundamentals are only growing stronger for this Biotech, our cash reserves have increased, commercialization now a reality and new health studies already initiated to further commercialize Promarker platform.
There is also the Therapeutics/Drug Division division that Richard has under his sleeve which is yet to see a strategic commercialization plan.
So far so good in my opinion
Ann: Proteomics secures major contract - nears cash flow positive, page-66
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.65M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 38.0¢ | $98.01K | 252.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9722 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 44999 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |